Novartis extends deal to make Pfizer/BioNTech vaccines
Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using manufacturing facilities Ljubljana, Slovenia, to fill at least 24 million doses in 2022. Novartis plans to take bulk mRNA active ingredient from BioNTech and fill this into vials under sterile conditions for shipment back to BioNTech for distribution.
